TY - JOUR
T1 - Specific plasma microRNAs are associated with CD4+T-cell recovery during suppressive antiretroviral therapy for HIV-1
AU - Kroeze, Stefanie
AU - Kootstra, Neeltje A.
AU - van Nuenen, Ad C.
AU - Rossouw, Theresa M.
AU - Kityo, Cissy M.
AU - Siwale, Margaret
AU - Akanmu, Sulaimon
AU - Mandaliya, Kishor
AU - de Jager, Marleen
AU - Ondoa, Pascale
AU - Wit, Ferdinand W.
AU - Reiss, Peter
AU - Rinke de Wit, Tobias F.
AU - Hamers, Raph L.
N1 - Publisher Copyright: © 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/5/1
Y1 - 2024/5/1
N2 - Objective:This study investigated the association of plasma microRNAs before and during antiretroviral therapy (ART) with poor CD4+T-cell recovery during the first year of ART.Design:MicroRNAs were retrospectively measured in stored plasma samples from people with HIV (PWH) in sub-Saharan Africa who were enrolled in a longitudinal multicountry cohort and who had plasma viral-load less than 50 copies/ml after 12 months of ART.Methods:First, the levels of 179 microRNAs were screened in a subset of participants from the lowest and highest tertiles of CD4+T-cell recovery (ΔCD4) (N = 12 each). Next, 11 discordant microRNAs, were validated in 113 participants (lowest tertile ΔCD4: n = 61, highest tertile ΔCD4: n = 52). For discordant microRNAs in the validation, a pathway analysis was conducted. Lastly, we compared microRNA levels of PWH to HIV-negative controls.Results:Poor CD4+T-cell recovery was associated with higher levels of hsa-miR-199a-3p and hsa-miR-200c-3p before ART, and of hsa-miR-17-5p and hsa-miR-501-3p during ART. Signaling by VEGF and MET, and RNA polymerase II transcription pathways were identified as possible targets of hsa-miR-199a-3p, hsa-200c-3p, and hsa-miR-17-5p. Compared with HIV-negative controls, we observed lower hsa-miR-326, hsa-miR-497-5p, and hsa-miR-501-3p levels before and during ART in all PWH, and higher hsa-miR-199a-3p and hsa-miR-200c-3p levels before ART in all PWH, and during ART in PWH with poor CD4+T-cell recovery only.Conclusion:These findings add to the understanding of pathways involved in persistent HIV-induced immune dysregulation during suppressive ART.
AB - Objective:This study investigated the association of plasma microRNAs before and during antiretroviral therapy (ART) with poor CD4+T-cell recovery during the first year of ART.Design:MicroRNAs were retrospectively measured in stored plasma samples from people with HIV (PWH) in sub-Saharan Africa who were enrolled in a longitudinal multicountry cohort and who had plasma viral-load less than 50 copies/ml after 12 months of ART.Methods:First, the levels of 179 microRNAs were screened in a subset of participants from the lowest and highest tertiles of CD4+T-cell recovery (ΔCD4) (N = 12 each). Next, 11 discordant microRNAs, were validated in 113 participants (lowest tertile ΔCD4: n = 61, highest tertile ΔCD4: n = 52). For discordant microRNAs in the validation, a pathway analysis was conducted. Lastly, we compared microRNA levels of PWH to HIV-negative controls.Results:Poor CD4+T-cell recovery was associated with higher levels of hsa-miR-199a-3p and hsa-miR-200c-3p before ART, and of hsa-miR-17-5p and hsa-miR-501-3p during ART. Signaling by VEGF and MET, and RNA polymerase II transcription pathways were identified as possible targets of hsa-miR-199a-3p, hsa-200c-3p, and hsa-miR-17-5p. Compared with HIV-negative controls, we observed lower hsa-miR-326, hsa-miR-497-5p, and hsa-miR-501-3p levels before and during ART in all PWH, and higher hsa-miR-199a-3p and hsa-miR-200c-3p levels before ART in all PWH, and during ART in PWH with poor CD4+T-cell recovery only.Conclusion:These findings add to the understanding of pathways involved in persistent HIV-induced immune dysregulation during suppressive ART.
KW - CD4 T-cell recovery
KW - HIV-1
KW - antiretroviral therapy
KW - immune dysregulation
KW - microRNA
UR - http://www.scopus.com/inward/record.url?scp=85190079084&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000003853
DO - 10.1097/QAD.0000000000003853
M3 - Article
C2 - 38300257
SN - 0269-9370
VL - 38
SP - 791
EP - 801
JO - AIDS
JF - AIDS
IS - 6
ER -